BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/17/2024 3:42:33 AM | Browse: 171 | Download: 1058
 |
Received |
|
2023-10-11 03:59 |
|
Peer-Review Started |
|
2023-10-11 04:00 |
|
First Decision by Editorial Office Director |
|
2023-12-26 04:53 |
|
Return for Revision |
|
2023-12-26 04:53 |
|
Revised |
|
2024-01-09 16:07 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-02-28 02:48 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-02-28 07:25 |
|
Articles in Press |
|
2024-02-28 07:25 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-04-10 01:55 |
|
Publish the Manuscript Online |
|
2024-04-17 03:42 |
| ISSN |
2220-3206 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Neurosciences |
| Manuscript Type |
Basic Study |
| Article Title |
Tanshinone IIA improves Alzheimer’s disease via RNA nuclear-enriched abundant transcript 1/microRNA-291a-3p/member RAS oncogene family Rab22a axis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Long-Xiu Yang, Man Luo and Sheng-Yu Li |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| 2020 Guangxi Zhuang Autonomous Region Health Care Commission Self-Financing Research Projects |
Z20200096 |
| 2023 Guangxi University Young and Middle-Aged Teachers’ Basic Research Ability Improvement Project |
2023KY0091 |
| National Natural Science Foundation of China |
82260241 |
| Natural Science Foundation of Guangxi Province |
2015GXNSFAA139171, 2020GXNSFAA259053 |
|
| Corresponding Author |
Sheng-Yu Li, MD, Doctor, Doctor, Teacher, Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Qingxiu District, Nanning 530000, Guangxi Zhuang Autonomous Region, China. 15177821212@163.com |
| Key Words |
Tanshinone IIA; Alzheimer’s disease; Nuclear-enriched abundant transcript 1; Member of RAS oncogene family Rab22a; Reactive oxygen species |
| Core Tip |
Tanshinone IIA (Tan-IIA), a compound isolated from Salvia miltiorrhiza, demonstrates neuroprotective effects against Alzheimer’s disease (AD). This study reveals that Tan-IIA improves neuronal health, reduces oxidative stress and neuroinflammation, and promotes neural stem cell viability. Importantly, it targets the nuclear-enriched abundant transcript 1/microRNA-291a-3p/member RAS oncogene family Rab22a/nuclear factor kappa-B pathway, offering a potential therapeutic avenue for AD. |
| Publish Date |
2024-04-17 03:42 |
| Citation |
Yang LX, Luo M, Li SY. Tanshinone IIA improves Alzheimer’s disease via RNA nuclear-enriched abundant transcript 1/microRNA-291a-3p/member RAS oncogene family Rab22a axis. World J Psychiatry 2024; 14(4): 563-581 |
| URL |
https://www.wjgnet.com/2220-3206/full/v14/i4/563.htm |
| DOI |
https://dx.doi.org/10.5498/wjp.v14.i4.563 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
